UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Endometriosis: Treatment of pelvic pain

Author
Robert S Schenken, MD
Section Editor
Robert L Barbieri, MD
Deputy Editor
Kristen Eckler, MD, FACOG

INTRODUCTION

Endometriosis, which is characterized by endometrial implants outside of the endometrial cavity, is a chronic disease that requires a lifelong management plan. Despite extensive research, the optimal management of endometriosis and its related symptoms is unclear. This topic will review medical and surgical options for treating pelvic pain caused by endometriosis.

Other topics related to endometriosis are discussed separately:

(See "Endometriosis: Pathogenesis, clinical features, and diagnosis".)

(See "Endometriosis: Surgical management of pelvic pain".)

(See "Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists".)

                         

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2016. | This topic last updated: Jun 13, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril 2014; 101:927.
  2. Pall M, Fridén BE, Brännström M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum Reprod 2001; 16:1323.
  3. Duffy DM, VandeVoort CA. Maturation and fertilization of nonhuman primate oocytes are compromised by oral administration of a cyclooxygenase-2 inhibitor. Fertil Steril 2011; 95:1256.
  4. Bata MS, Al-Ramahi M, Salhab AS, et al. Delay of ovulation by meloxicam in healthy cycling volunteers: A placebo-controlled, double-blind, crossover study. J Clin Pharmacol 2006; 46:925.
  5. Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014; 29:400.
  6. Practice bulletin no. 114: management of endometriosis. Obstet Gynecol 2010; 116:223.
  7. Mäkäräinen L, Rönnberg L, Kauppila A. Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertil Steril 1996; 65:29.
  8. Bergqvist A, Jacobson J, Harris S. A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone. Gynecol Endocrinol 1997; 11:187.
  9. Taskin O, Yalcinoglu AI, Kucuk S, et al. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril 1997; 67:40.
  10. Moghissi KS, Schlaff WD, Olive DL, et al. Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril 1998; 69:1056.
  11. Hughes E, Brown J, Collins JJ, et al. Ovulation suppression for endometriosis. Cochrane Database Syst Rev 2007; :CD000155.
  12. Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010; :CD001751.
  13. Allen C, Hopewell S, Prentice A, Gregory D. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev 2009; :CD004753.
  14. Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet 2015; 292:37.
  15. Vercellini P, Frontino G, De Giorgi O, et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80:560.
  16. Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril 2010; 93:2150.
  17. Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008; 90:1583.
  18. Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993; 60:75.
  19. Muzii L, Di Tucci C, Achilli C, et al. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. Am J Obstet Gynecol 2016; 214:203.
  20. Davis L, Kennedy SS, Moore J, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007; :CD001019.
  21. Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ 2014; 348:g1752.
  22. Olive DL. Medical therapy of endometriosis. Semin Reprod Med 2003; 21:209.
  23. Vessey MP, Villard-Mackintosh L, Painter R. Epidemiology of endometriosis in women attending family planning clinics. BMJ 1993; 306:182.
  24. Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2012; :CD002122.
  25. Andres Mde P, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet 2015; 292:523.
  26. Medroxyprogesterone acetate injection. US Food and Drug Administration (FDA) approved product information. Revised April 6, 2016. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov: accessed April 12, 2016)
  27. Dienogest. US Food and Drug Administration (FDA) approved product information. Revised August 5, 2015. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov (accessed April 12, 2016)).
  28. Norethindrone acetate tablet. US Food and Drug Administration (FDA) approved product information. Revised October, 2015. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov (accessed April 12, 2016)).
  29. Vercellini P, Bracco B, Mosconi P, et al. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril 2016; 105:734.
  30. Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update 2012; 18:682.
  31. Cirkel, U, Schweppe, KW, Ochs, H, et al. Effects of LHRH agonist therapy in the treatment of endometriosis. In: Gonadotropin down-regulation in gynecological practice. Vol 225, Chadha, DR, Willemsen, WNP (Eds). Aln R Liss, New York 1986. p. 189.
  32. Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. Contraception 2009; 79:29.
  33. Yisa SB, Okenwa AA, Husemeyer RP. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon). J Fam Plann Reprod Health Care 2005; 31:67.
  34. Vercellini P, Frontino G, De Giorgi O, et al. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 2003; 80:305.
  35. Bayoglu Tekin Y, Dilbaz B, Altinbas SK, Dilbaz S. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril 2011; 95:492.
  36. Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, et al. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: A randomized trial. Obstet Gynecol 2012.
  37. Wong AY, Tang LC, Chin RK. Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2010; 50:273.
  38. Dilbaz B, Ozdegirmenci O, Caliskan E, et al. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception 2010; 81:510.
  39. Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2010; :CD008475.
  40. Alkatout I, Mettler L, Beteta C, et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. J Minim Invasive Gynecol 2013; 20:473.
  41. Lupron Depot- leuprolide acetate 3.75 mg. US Food and Drug Administration (FDA) approved product information. Revised October 30, 2016. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60aad237-e1da-4705-cbbb-b3ca79e89ad8 (Accessed on March 29, 2016).
  42. Synarel- nafarelin acetate spray. US Food and Drug Administration (FDA) approved product information. Revised August 25, 2015. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0aa57cb-d2f4-46d7-af43-7c8b06aa81a6 (Accessed on March 29, 2016).
  43. Lupron Depot- leuprolide acetate 11.25 mg. US Food and Drug Administration (FDA) approved product information. Revised October 30, 2013. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60aad237-e1da-4705-cbbb-b3ca79e89ad8 (Accessed on March 29, 2016).
  44. Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003; :CD001297.
  45. Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2007; :CD000068.
  46. Telimaa S, Puolakka J, Rönnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol 1987; 1:13.
  47. Boothroyd CV, Lepre F. Permanent voice change resulting from Danazol therapy. Aust N Z J Obstet Gynaecol 1990; 30:275.
  48. Godin R, Marcoux V. Vaginally Administered Danazol: An Overlooked Option in the Treatment of Rectovaginal Endometriosis? J Obstet Gynaecol Can 2015; 37:1098.
  49. Attar E, Bulun SE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006; 85:1307.
  50. Mousa NA, Bedaiwy MA, Casper RF. Aromatase inhibitors in the treatment of severe endometriosis. Obstet Gynecol 2007; 109:1421.
  51. Bulun SE, Zeitoun K, Takayama K, et al. Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr Relat Cancer 1999; 6:293.
  52. Committee Opinion No. 663: Aromatase Inhibitors in Gynecologic Practice. Obstet Gynecol 2016; 127:e170.
  53. Nawathe A, Patwardhan S, Yates D, et al. Systematic review of the effects of aromatase inhibitors on pain associated with endometriosis. BJOG 2008; 115:818.
  54. Ferrero S, Camerini G, Seracchioli R, et al. Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. Hum Reprod 2009; 24:3033.
  55. Amsterdam LL, Gentry W, Jobanputra S, et al. Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril 2005; 84:300.
  56. Fritzer N, Tammaa A, Haas D, et al. When sex is not on fire: a prospective multicentre study evaluating the short-term effects of radical resection of endometriosis on quality of sex life and dyspareunia. Eur J Obstet Gynecol Reprod Biol 2016; 197:36.
  57. Chapron C, Vercellini P, Barakat H, et al. Management of ovarian endometriomas. Hum Reprod Update 2002; 8:591.
  58. Alborzi S, Zarei A, Alborzi S, Alborzi M. Management of ovarian endometrioma. Clin Obstet Gynecol 2006; 49:480.
  59. Benaglia L, Somigliana E, Vighi V, et al. Rate of severe ovarian damage following surgery for endometriomas. Hum Reprod 2010; 25:678.
  60. Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97:3146.
  61. Fedele L, Bianchi S, Zanconato G, et al. Is rectovaginal endometriosis a progressive disease? Am J Obstet Gynecol 2004; 191:1539.
  62. Westney OL, Amundsen CL, McGuire EJ. Bladder endometriosis: conservative management. J Urol 2000; 163:1814.
  63. Fedele L, Bianchi S, Montefusco S, et al. A gonadotropin-releasing hormone agonist versus a continuous oral contraceptive pill in the treatment of bladder endometriosis. Fertil Steril 2008; 90:183.
  64. Abrão MS, Petraglia F, Falcone T, et al. Deep endometriosis infiltrating the recto-sigmoid: critical factors to consider before management. Hum Reprod Update 2015; 21:329.
  65. Alifano M, Jablonski C, Kadiri H, et al. Catamenial and noncatamenial, endometriosis-related or nonendometriosis-related pneumothorax referred for surgery. Am J Respir Crit Care Med 2007; 176:1048.
  66. Leong AC, Coonar AS, Lang-Lazdunski L. Catamenial pneumothorax: surgical repair of the diaphragm and hormone treatment. Ann R Coll Surg Engl 2006; 88:547.
  67. Korom S, Canyurt H, Missbach A, et al. Catamenial pneumothorax revisited: clinical approach and systematic review of the literature. J Thorac Cardiovasc Surg 2004; 128:502.
  68. Joseph J, Sahn SA. Thoracic endometriosis syndrome: new observations from an analysis of 110 cases. Am J Med 1996; 100:164.
  69. Visouli AN, Darwiche K, Mpakas A, et al. Catamenial pneumothorax: a rare entity? Report of 5 cases and review of the literature. J Thorac Dis 2012; 4 Suppl 1:17.
  70. Marshall MB, Ahmed Z, Kucharczuk JC, et al. Catamenial pneumothorax: optimal hormonal and surgical management. Eur J Cardiothorac Surg 2005; 27:662.
  71. Koizumi T, Inagaki H, Takabayashi Y, Kubo K. Successful use of gonadotropin-releasing hormone agonist in a patient with pulmonary endometriosis. Respiration 1999; 66:544.
  72. Slabbynck H, Laureys M, Impens N, et al. Recurring catamenial pneumothorax treated with a Gn-RH analogue. Chest 1991; 100:851.
  73. Uemura T, Matsuyama A, Minaguchi H, Ikeda H. Danazol (an antigonadotropin) in the treatment of catamenial pneumothorax. Asia Oceania J Obstet Gynaecol 1985; 11:81.
  74. Akal M, Kara M. Nonsurgical treatment of a catamenial pneumothorax with a Gn-RH analogue. Respiration 2002; 69:275.
  75. Attaran S, Bille A, Karenovics W, Lang-Lazdunski L. Videothoracoscopic repair of diaphragm and pleurectomy/abrasion in patients with catamenial pneumothorax: a 9-year experience. Chest 2013; 143:1066.
  76. Zhu X, Hamilton KD, McNicol ED. Acupuncture for pain in endometriosis. Cochrane Database Syst Rev 2011; :CD007864.
  77. Xiang D, Situ Y, Liang X, et al. Ear acupuncture therapy for 37 cases of dysmenorrhea due to endometriosis. J Tradit Chin Med 2002; 22:282.
  78. Parazzini F, Chiaffarino F, Surace M, et al. Selected food intake and risk of endometriosis. Hum Reprod 2004; 19:1755.